Roche: sells Genentech plant for $1.2bn

(CercleFinance.com) - Roche has announced that it has reached a definitive agreement with Lonza, which will acquire the Genentech manufacturing facility in Vacaville, California (US) for $1.
2bn.

Under the terms of the agreement, the 750 or so Genentech employees at the Vacaville site will be offered employment by Lonza, and products currently manufactured at the site by Roche will continue to be supplied by Lonza during a transition period.

We have decided to divest our Vacaville site as part of our network strategy and long-term optimization plan, in order to offer a more diversified portfolio including new drug modalities, it said.

The transaction is expected to close by H2 2024.


Copyright (c) 2024 CercleFinance.com. All rights reserved.